Teruhisa Kato Selected Research

N- (2- hydroxyethyl)- N,2- dimethyl- 8- ((5- methyl- 3,4- dihydro- 2H- chromen- 4- yl)amino)imidazo(1,2- a)pyridine- 6- carboxamide

2/2009

N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Teruhisa Kato Research Topics

Disease

1	COVID-19 12/2022
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Malaria 01/2022
1	Pain (Aches) 08/2011
1	Gastroesophageal Reflux (GERD) 02/2009
1	Hepatocellular Carcinoma (Hepatoma) 08/2008

Drug/Important Bio-Agent (IBA)

1	ensitrelvirIBA 12/2022
1	Protease Inhibitors (Protease Inhibitor)IBA 12/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	VaccinesIBA 01/2022
1	Ion Channels (Ion Channel)IBA 08/2011
1	Proton Pump InhibitorsIBA 02/2009
1	pyridineIBA 02/2009
1	N- (2- hydroxyethyl)- N,2- dimethyl- 8- ((5- methyl- 3,4- dihydro- 2H- chromen- 4- yl)amino)imidazo(1,2- a)pyridine- 6- carboxamideIBA 02/2009
1	AcidsIBA 02/2009
1	Histamine (Histamine Dihydrochloride)FDA Link 02/2009
1	LigandsIBA 08/2008

Therapy/Procedure

1	Therapeutics 02/2009